Table 3.
Adverse events for participating patients with metastatic colorectal cancer
| ER + BV + FOLFOX4 (n = 66) | BV + FOLFOX4 (n = 65) | |||
|---|---|---|---|---|
|
|
||||
| AE | All events | Grade 3 & 4 events | All events | Grade 3 & 4 events |
|
|
||||
| Patients, n (%) | Patients, n (%) | |||
| Bleeding | 23 (34.8%) | 10 (15.2%) | 11 (16.9%) | 3 (4.6%) |
| Vomiting | 27 (40.9%) | 13 (19.7%) | 16 (24.6%) | 7 (10.8%) |
| Rash | 25 (38.5%) | 20 (30.3%) | 20 (30.1%) | 12 (18.5%) |
| Neuropathy | 26 (39.4%) | 18 (27.2%) | 17 (26.2%) | 13 (20.0%) |
| Diarrhea | 13 (19.7%) | 8 (12.1%) | 6 (9.2%) | 3 (4.6%) |
| Fatigue | 24 (36.4%) | 11 (16.7%) | 12 (18.5%) | 5 (7.7%) |
| Proteinuria | 9 (13.6%) | 3 (4.5%) | 4 (6.2%) | 1 (1.5%) |
| Thrombocytopenia | 15 (23.1%) | 7 (10.6%) | 8 (12.3%) | 3 (4.6%) |
| Heart Failure | 10 (15.2%) | 4 (6.1%) | 5 (7.7%) | 2 (3.1%) |
| Asthenia | 5 (7.6%) | 3 (4.5%) | 7 (10.8%) | 1 (1.5%) |
| Anemia | 6 (9.1%) | 2 (3.0%) | 3 (4.6%) | 1 (1.5%) |
Abbreviations: AE, adverse events.